---
title: FDA Issues New Guidance on Suspect and Illegitimate Product
description: This blog posts provides a summary overview of the recent FDA Guidance on Suspect and Illegitimate Product Definitions.
image: https://info.consortiex.com/hubfs/FDAGuidanceSocialImage.png
---

[![ConsortiEX](https://info.consortiex.com/hubfs/ConsortiEX_January2020%20Theme/images/ConsortiEX_2.png)![ConsortiEX](https://info.consortiex.com/hubfs/ConsortiEX_January2020%20Theme/images/ConsortiEX_2.png "ConsortiEX")](https://www.consortiex.com)

- [Home](https://consortiex.com/)
- Solutions 
    - [Assure-Trak® | 503B](https://consortiex.com/outsourcing-facility-503b/)
    - [Assure-Trak® | Health System](https://consortiex.com/health-system/)
    - [DSCSA Compliance](https://consortiex.com/dscsa-compliance/)
    - [Verify on Receipt™](https://consortiex.com/verify-on-receipt/)
- [ConsortiEX Blog](https://info.consortiex.com/blog)
- More 
    - [About ConsortiEX](https://www.consortiex.com/about-consortiex/)
    - [Meet the Team](https://www.consortiex.com/meet-our-team/)
    - [Resources](https://info.consortiex.com/resources)
    - [DSCSA Resources](https://consortiex.com/dscsa-resources/)
- Contact 
    - [Current Customer Support](https://consortiex.com/support/)
    - [Request a Demo](https://consortiex.com/contact-us/)

- [Home](https://consortiex.com/)
- Solutions 
    - [Assure-Trak® | 503B](https://consortiex.com/outsourcing-facility-503b/)
    - [Assure-Trak® | Health System](https://consortiex.com/health-system/)
    - [DSCSA Compliance](https://consortiex.com/dscsa-compliance/)
    - [Verify on Receipt™](https://consortiex.com/verify-on-receipt/)
- [ConsortiEX Blog](https://info.consortiex.com/blog)
- More 
    - [About ConsortiEX](https://www.consortiex.com/about-consortiex/)
    - [Meet the Team](https://www.consortiex.com/meet-our-team/)
    - [Resources](https://info.consortiex.com/resources)
    - [DSCSA Resources](https://consortiex.com/dscsa-resources/)
- Contact 
    - [Current Customer Support](https://consortiex.com/support/)
    - [Request a Demo](https://consortiex.com/contact-us/)

April 19, 2023

# FDA Issues New Guidance on Suspect and Illegitimate Product

The FDA recently issued guidance on the definition of Suspect and Illegitimate Products, set forth in the Federal Food Drug and Cosmetic Act1. This guidance aims to assist trading partners in putting systems in place to identify and handle suspect and illegitimate products, meeting Drug Supply Chain Security Act (DSCSA)2 requirements.

Trading partners are required to take action if they encounter suspect or illegitimate product.

Find a summary of the recent guidance below:

***As defined in DSCSA upon its signing in 2013***

DSCSA requires trading partners to identify suspect product that enters its supply chain *and* have the ability to determine whether that product is illegitimate. According to the FDA, trading partners should focus on identifying products that are, or may be: *counterfeit, diverted, stolen, intentionally adulterated, unfit for distribution, or the subject of a fraudulent transaction.*

See clarifications on these definitions below.

**Counterfeit** – a drug, container, or drug label, which bears an unauthorized trademark, trade name, identifying mark, or any likeness thereof, of a manufacturer, processor, or distributor, other than the actual manufacturer, processor, or distributor, of such drug, thereby falsely representing itself as a product of the manufacturer, processor, or distributor.

**Diverted** – a product that leaves, and is then reintroduced, into the US Pharmaceutical Supply Chain; product that is for sale in a non-US market, which is then introduced into the US Supply Chain. Exceptions include: products that are authorized in response to FDA action (i.e, drug shortages), products used in the event of Emergency Use Authorization, products obtained through surveillance activities.

**Stolen** – Any product, packaging of a product, or prescription drug, that has been taken or removed without permissions of the owner of such product, or that is missing any or all portions of the drug as a result of being taken or removed without the permission of the owner. This includes packages, down to individual pills/capsules.

*Consult the guidance: Drug Supply Chain Security Act Implementation: Identification of Suspect Product and Notification, for guidance on identification of suspect and illegitimate product. -* [\[Link\]](https://www.fda.gov/media/88790/download)

**Fraudulent Transaction** – A transaction in which the \[transaction\] information, history, or statement contains information that was intentionally falsified by a trading partner.

Note: The FDA is aware that data errors, or other circumstances, may yield inaccurate transaction information where the data was not *knowingly* falsified. This is why trading partners must take steps to investigate all occurrences, to determine if a product is illegitimate.

**Unfit for Distribution** – a prescription drug that is nonsaleable because its sale would be violate the FD&C Act, *and* there is reason to believe its use would reasonably result in serious adverse events or death in humans.

Products are often deemed unfit due to doubts of the products *safety, identity, strength quality or purity*, to the extent that use of the product may reasonably result in serious adverse health events or death in humans.

The FDA recognizes that non-salable products are often removed from the supply chain without triggering investigation (expired drugs, reverse distribution). *Only non-salable products that may otherwise reach a patient should be treated as suspect or illegitimate.* However, these products should still be investigated should they meet any additional criteria outlined above.

To access the full FDA guidance, click here: [\[Link\]](https://www.fda.gov/media/111468/download)

\* \* \*

Thanks to Verify on Receipt and DSCSA Compliance as a Service, ConsortiEX is the industry leading DQSA Compliance provider.

[Verify on Receipt™](https://consortiex.com/verify-on-receipt/) - the premier DSCSA compliance solution from ConsortiEX, as an industry best practice, Verify on Receipt use of barcode scanning technology optimizes your workflows, accomplishing more than meeting compliance standards. 

[DSCSA Compliance as a Service](https://consortiex.com/dscsa-compliance/) - The solution that made ConsortiEX what it is today. DSCSA Compliance as a Service makes your compliance, our compliance

Assure-Trak® Compounding Management System - The only IV Workflow Management System currently meeting the needs of [503B Outsourcing Facilities](https://consortiex.com/outsourcing-facility-503b/) and [Health System Pharmacies](https://consortiex.com/health-system/)

If you have any concerns about your compliance, or anything else, [contact us today](https://consortiex.com/contact-us/)!

*1 - Suspect: Section 581(21) of the FD&C Act)(21 U.S.C.360eee(21)  
2- The Drug Supply Chain Security Act amended the FD&C to establish requirements for certain drug products in the United States*

 

 

[Customer Spotlight | RC Outsourcing](https://info.consortiex.com/blog/customer-spotlight-rc-outsourcing) [FDA Updates Messaging to Compounders Nationwide](https://info.consortiex.com/blog/fda-updates-messaging-to-compounders-nationwide)

### Related Posts

## [ConsortiEX and LedgerDomain Announce Strategic Partnership](https://info.consortiex.com/blog/consortiex-and-ledgerdomain-announce-strategic-partnership)

## [ConsortiEX | ASHP Midyear 2023](https://info.consortiex.com/blog/consortiex-ashp-midyear-2023)

## [DSCSA Debunked; Myths vs. Reality](https://info.consortiex.com/blog/dscsa-debunked-myths-vs.-reality)

### Recent Posts

- [In Response to the FDA Announcement](https://info.consortiex.com/blog/in-response-to-the-fda)   
  October 11, 2024
- [ConsortiEX Soars to Support Dream Flights, and US Veterans](https://info.consortiex.com/blog/consortiex-supports-dream-flights)   
  August 6, 2024
- [ConsortiEX and LedgerDomain Announce Strategic Partnership](https://info.consortiex.com/blog/consortiex-and-ledgerdomain-announce-strategic-partnership)   
  March 13, 2024

### Topics

- [ConsortiEX (22)](https://info.consortiex.com/blog/tag/consortiex)
- [DSCSA (21)](https://info.consortiex.com/blog/tag/dscsa)
- [DQSA (18)](https://info.consortiex.com/blog/tag/dqsa)
- [FDA (18)](https://info.consortiex.com/blog/tag/fda)
- [Compounding (17)](https://info.consortiex.com/blog/tag/compounding)
- [batch compounding (16)](https://info.consortiex.com/blog/tag/batch-compounding)
- [drug quality and security act (16)](https://info.consortiex.com/blog/tag/drug-quality-and-security-act)
- [patient safety (16)](https://info.consortiex.com/blog/tag/patient-safety)
- [assure-trak (15)](https://info.consortiex.com/blog/tag/assure-trak)
- [Blog (14)](https://info.consortiex.com/blog/tag/blog)
- [Track and Trace (13)](https://info.consortiex.com/blog/tag/track-and-trace)
- [Drug Supply Chain Security Act (12)](https://info.consortiex.com/blog/tag/drug-supply-chain-security-act)
- [IV workflow software (12)](https://info.consortiex.com/blog/tag/iv-workflow-software)
- [Industry (12)](https://info.consortiex.com/blog/tag/industry)
- [Pharmacy IT software (11)](https://info.consortiex.com/blog/tag/pharmacy-it-software)
- [health care pharmacy (11)](https://info.consortiex.com/blog/tag/health-care-pharmacy)
- [iv workflow (11)](https://info.consortiex.com/blog/tag/iv-workflow)
- [503B (10)](https://info.consortiex.com/blog/tag/503b)
- [503A (9)](https://info.consortiex.com/blog/tag/503a)
- [compliance (9)](https://info.consortiex.com/blog/tag/compliance)
- [iv workflow management (9)](https://info.consortiex.com/blog/tag/iv-workflow-management)
- [Total Ingredient Life Cycle (8)](https://info.consortiex.com/blog/tag/total-ingredient-life-cycle)
- [enterprise resource planning (8)](https://info.consortiex.com/blog/tag/enterprise-resource-planning)
- [pedigree to patient (8)](https://info.consortiex.com/blog/tag/pedigree-to-patient)
- [pharmacy software (8)](https://info.consortiex.com/blog/tag/pharmacy-software)
- [traceability (8)](https://info.consortiex.com/blog/tag/traceability)
- [USP (7)](https://info.consortiex.com/blog/tag/usp)
- [anticipatory compounding (7)](https://info.consortiex.com/blog/tag/anticipatory-compounding)
- [assure-track (6)](https://info.consortiex.com/blog/tag/assure-track)
- [pharmaceutical compounding (6)](https://info.consortiex.com/blog/tag/pharmaceutical-compounding)
- [Spotlight (5)](https://info.consortiex.com/blog/tag/spotlight)
- [compounded sterile preparations (5)](https://info.consortiex.com/blog/tag/compounded-sterile-preparations)
- [compounded sterile productions (5)](https://info.consortiex.com/blog/tag/compounded-sterile-productions)
- [pharmacy (5)](https://info.consortiex.com/blog/tag/pharmacy)
- [pharmacy it (5)](https://info.consortiex.com/blog/tag/pharmacy-it)
- [quality assurance (5)](https://info.consortiex.com/blog/tag/quality-assurance)
- [DSCSA Compliance (4)](https://info.consortiex.com/blog/tag/dscsa-compliance)
- [EDI (4)](https://info.consortiex.com/blog/tag/edi)
- [News (4)](https://info.consortiex.com/blog/tag/news)
- [T3 Documentation (4)](https://info.consortiex.com/blog/tag/t3-documentation)
- [USP 797 (4)](https://info.consortiex.com/blog/tag/usp-797)
- [clean room (4)](https://info.consortiex.com/blog/tag/clean-room)
- [compounded IV bags (4)](https://info.consortiex.com/blog/tag/compounded-iv-bags)
- [compounded syringe (4)](https://info.consortiex.com/blog/tag/compounded-syringe)
- [drug serialization (4)](https://info.consortiex.com/blog/tag/drug-serialization)
- [order management (4)](https://info.consortiex.com/blog/tag/order-management)
- [sterile product compounding (4)](https://info.consortiex.com/blog/tag/sterile-product-compounding)
- [transaction history transaction information transa (4)](https://info.consortiex.com/blog/tag/transaction-history-transaction-information-transa)
- [DQSA - USP 797 (3)](https://info.consortiex.com/blog/tag/dqsa-usp-797)
- [DSCSA CaaS (3)](https://info.consortiex.com/blog/tag/dscsa-caas)
- [DSCSA Software (3)](https://info.consortiex.com/blog/tag/dscsa-software)
- [Drug Counterfeiting (3)](https://info.consortiex.com/blog/tag/drug-counterfeiting)
- [EPCIS (3)](https://info.consortiex.com/blog/tag/epcis)
- [Requirements (3)](https://info.consortiex.com/blog/tag/requirements)
- [drug borrow loan (3)](https://info.consortiex.com/blog/tag/drug-borrow-loan)
- [dscsa compliance as a service 3T (3)](https://info.consortiex.com/blog/tag/dscsa-compliance-as-a-service-3t)
- [exchange (3)](https://info.consortiex.com/blog/tag/exchange)
- [guidance (3)](https://info.consortiex.com/blog/tag/guidance)
- [illegitimate product (3)](https://info.consortiex.com/blog/tag/illegitimate-product)
- [pharmacy erp (3)](https://info.consortiex.com/blog/tag/pharmacy-erp)
- [suspect product (3)](https://info.consortiex.com/blog/tag/suspect-product)
- [3Ts (2)](https://info.consortiex.com/blog/tag/3ts)
- [ASHP (2)](https://info.consortiex.com/blog/tag/ashp)
- [COVID-19 (2)](https://info.consortiex.com/blog/tag/covid-19)
- [Compliance as a Service (2)](https://info.consortiex.com/blog/tag/compliance-as-a-service)
- [Compounding Pharmacy (2)](https://info.consortiex.com/blog/tag/compounding-pharmacy)
- [DSCSA service (2)](https://info.consortiex.com/blog/tag/dscsa-service)
- [DSCSA software and service (2)](https://info.consortiex.com/blog/tag/dscsa-software-and-service)
- [Data Entry (2)](https://info.consortiex.com/blog/tag/data-entry)
- [Drug supply chain transparency (2)](https://info.consortiex.com/blog/tag/drug-supply-chain-transparency)
- [Electronic Data Interchange (2)](https://info.consortiex.com/blog/tag/electronic-data-interchange)
- [Environmental monitoring (2)](https://info.consortiex.com/blog/tag/environmental-monitoring)
- [Manual T3 Conversion (2)](https://info.consortiex.com/blog/tag/manual-t3-conversion)
- [NDC tracking (2)](https://info.consortiex.com/blog/tag/ndc-tracking)
- [Passive auditing (2)](https://info.consortiex.com/blog/tag/passive-auditing)
- [Prescription tracking (2)](https://info.consortiex.com/blog/tag/prescription-tracking)
- [T3 (2)](https://info.consortiex.com/blog/tag/t3)
- [T3 Conversion (2)](https://info.consortiex.com/blog/tag/t3-conversion)
- [T3s (2)](https://info.consortiex.com/blog/tag/t3s)
- [compounded IV bag (2)](https://info.consortiex.com/blog/tag/compounded-iv-bag)
- [compounded syringes (2)](https://info.consortiex.com/blog/tag/compounded-syringes)
- [drug supply chain (2)](https://info.consortiex.com/blog/tag/drug-supply-chain)
- [drug transfers (2)](https://info.consortiex.com/blog/tag/drug-transfers)
- [dscsa deadline (2)](https://info.consortiex.com/blog/tag/dscsa-deadline)
- [fda guidance (2)](https://info.consortiex.com/blog/tag/fda-guidance)
- [patient specific compounding (2)](https://info.consortiex.com/blog/tag/patient-specific-compounding)
- [pharmacy serialization (2)](https://info.consortiex.com/blog/tag/pharmacy-serialization)
- [pharmacy supply chain (2)](https://info.consortiex.com/blog/tag/pharmacy-supply-chain)
- [product (2)](https://info.consortiex.com/blog/tag/product)
- [product identifier (2)](https://info.consortiex.com/blog/tag/product-identifier)
- [quarantine (2)](https://info.consortiex.com/blog/tag/quarantine)
- [regulation (2)](https://info.consortiex.com/blog/tag/regulation)
- [serialization (2)](https://info.consortiex.com/blog/tag/serialization)
- [sterile injectable compound (2)](https://info.consortiex.com/blog/tag/sterile-injectable-compound)
- [vaccine (2)](https://info.consortiex.com/blog/tag/vaccine)
- [503B. outsourcing facility (1)](https://info.consortiex.com/blog/tag/503b-outsourcing-facility)
- [Bar Code Medication Verification (1)](https://info.consortiex.com/blog/tag/bar-code-medication-verification)
- [Central Sterile Compounding (1)](https://info.consortiex.com/blog/tag/central-sterile-compounding)
- [Cleanroom (1)](https://info.consortiex.com/blog/tag/cleanroom)
- [Compounding Quality Act (1)](https://info.consortiex.com/blog/tag/compounding-quality-act)
- [ISMP (1)](https://info.consortiex.com/blog/tag/ismp)
- [Pharmacy Informatics (1)](https://info.consortiex.com/blog/tag/pharmacy-informatics)
- [Technology Assisted IV Workflow Software (1)](https://info.consortiex.com/blog/tag/technology-assisted-iv-workflow-software)
- [USP . USP 800 (1)](https://info.consortiex.com/blog/tag/usp-usp-800)
- [audit (1)](https://info.consortiex.com/blog/tag/audit)
- [barcode (1)](https://info.consortiex.com/blog/tag/barcode)
- [central-fill (1)](https://info.consortiex.com/blog/tag/central-fill)
- [community involvement (1)](https://info.consortiex.com/blog/tag/community-involvement)
- [compounding management system (1)](https://info.consortiex.com/blog/tag/compounding-management-system)
- [deadline (1)](https://info.consortiex.com/blog/tag/deadline)
- [draft guidance (1)](https://info.consortiex.com/blog/tag/draft-guidance)
- [drug loan borrow (1)](https://info.consortiex.com/blog/tag/drug-loan-borrow)
- [drug waste (1)](https://info.consortiex.com/blog/tag/drug-waste)
- [dynamic patient specific (1)](https://info.consortiex.com/blog/tag/dynamic-patient-specific)
- [grandfathered (1)](https://info.consortiex.com/blog/tag/grandfathered)
- [grandfathered product (1)](https://info.consortiex.com/blog/tag/grandfathered-product)
- [software (1)](https://info.consortiex.com/blog/tag/software)
- [specialty compounding (1)](https://info.consortiex.com/blog/tag/specialty-compounding)
- [verification systems (1)](https://info.consortiex.com/blog/tag/verification-systems)

See all

[![ConsortiEX](https://info.consortiex.com/hubfs/ConsortiEX_January2020%20Theme/images/ConsortiEX_2.png)](http://acc-dev.consortiex.com/)

- <https://twitter.com/ConsortiEX>
- <https://www.linkedin.com/company/10680398/>

*733 N Van Buren St, Ste 501*  
*Milwaukee, WI 53202*

*Office: (414) 231-4575*   
*Support: (888) 434-1442*

*Email: info@consortiex.com*

- [Homepage](https://www.consortiex.com/)
- [About ConsortiEX](https://www.consortiex.com/about-consortiex/)
- [Blog](https://info.consortiex.com/blog)
- [Contact Us](https://www.consortiex.com/contact-us/)
- [DSCSA Compliance](https://www.consortiex.com/dscsa-compliance/)
- [Health System](https://www.consortiex.com/health-system/)
- [Magnifier™ Analytics](https://consortiex.com/consortiex-magnifier-analytics/)
- [Outsourcing Facility 503B](https://www.consortiex.com/outsourcing-facility-503b/)
- [Resources](https://info.consortiex.com/resources)

 2025 | ConsortiEX Inc. | All Rights Reserved